Alternative RNA Splicing in the Pathogenesis of GBM

Alternative splicing enables the generation of different proteins from a single gene, greatly increasing the use of genetic information. The resultant protein isoforms often have different biological properties effecting the phenotype of the cell in which it is expressed. Dysregulation of alternative splicing is a common occurrence in cancer and may lead to the formation of truncated or degraded proteins through the introduction of immature stop codons or nonsense mediated decay.  Increasing evidence indicates that cancer-associated splicing variants play an important role in tumor initiation and progression. In this review, we summarize the evidence supporting the relevance of alternative splicing in glioblastoma multiforme (GBM). Specifically, we focus on the role of alternative splicing in GBM pathogenesis with an emphasis on the effect of aberrant alternative splicing of FGFR, GLI-1, and EGFR. The significance of exploiting alternatively spliced isoforms as potential biomarkers which may contribute to the development of diagnostic and prognostic methods, in addition to serving as molecular targets in GBM, will be discussed.

[1]  F. Yu,et al.  Identification of differential splicing genes in gliomas using exon expression profiling , 2014, Molecular medicine reports.

[2]  Hiroshi Yamamoto,et al.  RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. , 2014, Cancer research.

[3]  Zongwei Li,et al.  The multifaceted regulation and functions of PKM2 in tumor progression. , 2014, Biochimica et biophysica acta.

[4]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[5]  E. Makeyev,et al.  Regulation of mRNA Abundance by Polypyrimidine Tract-Binding Protein-Controlled Alternate 5′ Splice Site Choice , 2014, PLoS genetics.

[6]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[7]  D. Scholtens,et al.  Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. , 2014, The Journal of clinical investigation.

[8]  J. C. Love,et al.  EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. , 2014, Cancer discovery.

[9]  J. Sarkaria,et al.  EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180 , 2014, Oncogene.

[10]  Hu Zhu,et al.  The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. , 2014, Cancer letters.

[11]  S. Nelson,et al.  Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.

[12]  P. Taneja,et al.  AR-A 014418 Used against GSK3beta Downregulates Expression of hnRNPA1 and SF2/ASF Splicing Factors , 2014, Journal of oncology.

[13]  Yu Zhou,et al.  De Novo Prediction of PTBP1 Binding and Splicing Targets Reveals Unexpected Features of Its RNA Recognition and Function , 2014, PLoS Comput. Biol..

[14]  Zefeng Wang,et al.  A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.

[15]  C. Brennan,et al.  Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates , 2013, Acta Neuropathologica.

[16]  D. Maiguel,et al.  Alternative Splicing of the RAGE Cytoplasmic Domain Regulates Cell Signaling and Function , 2013, PloS one.

[17]  Xingzhong Guo,et al.  Identification and expression of a novel MDM4 splice variant in human glioma , 2013, Brain Research.

[18]  Jian Zhang,et al.  Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.

[19]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[20]  Lynda Chin,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:From the Cover: Neutralization of terminal differentiation in gliomagenesis , 2013 .

[21]  Douglas L Black,et al.  EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. , 2013, Cell metabolism.

[22]  Shinn-Zong Lin,et al.  Aberrant Alternative Splicing Events in Parkinson's Disease , 2013, Cell transplantation.

[23]  Ahmed Sadeque,et al.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival , 2012, BMC Medical Genomics.

[24]  R. Krahe,et al.  PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis , 2012, Molecular carcinogenesis.

[25]  A. Krainer,et al.  Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides , 2012, Open Biology.

[26]  Carine Maenhaut,et al.  Hallmarks of cancer: of all cancer cells, all the time? , 2012, Trends in molecular medicine.

[27]  E. Gottlieb,et al.  Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. , 2012, Trends in biochemical sciences.

[28]  A. Koong,et al.  A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors , 2012, Oncogene.

[29]  F. Caire,et al.  EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas , 2012, PloS one.

[30]  R. Carpenter,et al.  Hedgehog pathway and GLI1 isoforms in human cancer. , 2012, Discovery medicine.

[31]  I. Pommepuy,et al.  Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain , 2011, International journal of oncology.

[32]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[33]  Derek Y. Chiang,et al.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. , 2011, Cancer research.

[34]  C. Brennan,et al.  Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas , 2011, The EMBO journal.

[35]  L. Nie,et al.  Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma , 2011, Journal of Clinical Pathology.

[36]  Luigi Coppola,et al.  Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. , 2011, Cancer research.

[37]  Jianren Gu,et al.  Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. , 2011, Neoplasia.

[38]  M. Russo,et al.  Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma , 2011, Journal of Neuroinflammation.

[39]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[40]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[41]  S. Kalkanis,et al.  Heparanase expression of glioma in human and animal models. , 2010, Journal of neurosurgery.

[42]  F. White,et al.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism , 2010, Oncogene.

[43]  P. Lichter,et al.  Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells , 2010, Clinical Cancer Research.

[44]  A. Krainer,et al.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism , 2010, Proceedings of the National Academy of Sciences.

[45]  Ke Wang,et al.  Gli1 is a potential target for alleviating multidrug resistance of gliomas , 2010, Journal of the Neurological Sciences.

[46]  Paul S Mischel,et al.  Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.

[47]  F. Ali-Osman,et al.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. , 2009, Cancer research.

[48]  Wen Zhu,et al.  Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. , 2009, Brain : a journal of neurology.

[49]  A. Baron,et al.  Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. , 2009, IDrugs : the investigational drugs journal.

[50]  G. Riggins,et al.  Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling , 2009, Journal of Neuro-Oncology.

[51]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[52]  E. Nevo,et al.  Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis , 2009, Proceedings of the National Academy of Sciences.

[53]  K. Baggerly,et al.  Splicing factors PTBP 1 and PTBP 2 promote proliferation and migration of glioma cell lines , 2009 .

[54]  S. Stamm,et al.  Alternative splicing and disease. , 2009, Biochimica et biophysica acta.

[55]  R. Nieves-Alicea,et al.  Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. , 2008, Experimental cell research.

[56]  T. Mikkelsen,et al.  Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells , 2008, Journal of experimental & clinical cancer research : CR.

[57]  Duncan J. Smith,et al.  "Nought may endure but mutability": spliceosome dynamics and the regulation of splicing. , 2008, Molecular cell.

[58]  J. Sawada,et al.  Hypoxia induces expression of a GPI‐anchorless splice variant of the prion protein , 2008, The FEBS journal.

[59]  M. Kasper,et al.  Novel Human Glioma-associated Oncogene 1 (GLI1) Splice Variants Reveal Distinct Mechanisms in the Terminal Transduction of the Hedgehog Signal , 2008, Journal of Biological Chemistry.

[60]  Lili Wan,et al.  SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing , 2008, Cell.

[61]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  Christoph Straub,et al.  A brain-specific SGK1 splice isoform regulates expression of ASIC1 in neurons , 2008, Proceedings of the National Academy of Sciences.

[63]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[64]  G. Ast,et al.  Alternative splicing: current perspectives , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[65]  T. Mikkelsen,et al.  Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. , 2007, Biochemical and biophysical research communications.

[66]  F. Lang,et al.  Differential Regulation of Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) Splice Variants Based on Alternative Initiation of Transcription , 2007, Cellular Physiology and Biochemistry.

[67]  S. Friedman,et al.  Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma , 2007, International journal of cancer.

[68]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[69]  Douglas L Black,et al.  A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. , 2007, Genes & development.

[70]  N. Mulherkar,et al.  MADD/DENN Splice Variant of the IG20 Gene Is a Negative Regulator of Caspase-8 Activation , 2007, Journal of Biological Chemistry.

[71]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[72]  A. Scott,et al.  A phase I clinical trial with monoclonal antibody ch 806 targeting transitional state and mutant epidermal growth factor receptors , 2007 .

[73]  Xiuli Jiang,et al.  Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. , 2007, Cancer research.

[74]  S. Barnes,et al.  Cav3.1 splice variant expression during neuronal differentiation of Y-79 retinoblastoma cells , 2006, Neuroscience.

[75]  R. Salgia,et al.  Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas , 2006, Clinical Cancer Research.

[76]  G. Fuller,et al.  Polypyrimidine tract binding protein and Notch1 are independently re-expressed in glioma , 2006, Modern Pathology.

[77]  Dario Neri,et al.  Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C , 2006, Clinical Cancer Research.

[78]  K. Jellinger,et al.  The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2‐BETA1 changes in sporadic Alzheimer's disease , 2006, Journal of neurochemistry.

[79]  松下 博和 Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients , 2006 .

[80]  S. Friedman,et al.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. , 2005, Cancer research.

[81]  H. Mehdorn,et al.  Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.

[82]  Wei Zhang,et al.  Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. , 2005, Cancer research.

[83]  M. P. Holloway,et al.  Survivin splice variants regulate the balance between proliferation and cell death , 2005, Oncogene.

[84]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[85]  D. Schaid,et al.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. , 2005, Cancer research.

[86]  J. Kros,et al.  Differential expression of Hela‐type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells , 2005, The Journal of pathology.

[87]  Aaron M. Beedle,et al.  Expression of T‐type calcium channel splice variants in human glioma , 2004, Glia.

[88]  W. Jin,et al.  Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. , 2004, Human molecular genetics.

[89]  A. Sieuwerts,et al.  Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. , 2004, The American journal of pathology.

[90]  Jeon-Soo Shin,et al.  Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.

[91]  H. Kawami,et al.  Identification of an Alternatively Spliced RNA for the Ras Suppressor RSU-1 in Human Gliomas , 2002, Journal of Neuro-Oncology.

[92]  B. Zoll,et al.  Amplification and expression of the epidermal growth factor receptor gene during the progression of neuroepithelial tumours in vivo , 1992, Journal of Neurology.

[93]  T. Nilsen The spliceosome: the most complex macromolecular machine in the cell? , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[94]  Y. Kajimoto,et al.  Transcriptional expression of survivin and its splice variants in brain tumors in humans. , 2003, Journal of neurosurgery.

[95]  W. Jin,et al.  Polypyrimidine tract-binding protein down-regulates fibroblast growth factor receptor 1 alpha-exon inclusion. , 2003, Cancer research.

[96]  Chi-Ying F. Huang,et al.  Molecular characterization of human ninein protein: two distinct subdomains required for centrosomal targeting and regulating signals in cell cycle. , 2003, Biochemical and biophysical research communications.

[97]  K. Ozawa,et al.  Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator , 2003, Gene Therapy.

[98]  Kenneth M. Yamada,et al.  CrkI adapter protein modulates cell migration and invasion in glioblastoma. , 2003, Cancer research.

[99]  T. Cooper,et al.  Pre-mRNA splicing and human disease. , 2003, Genes & development.

[100]  A. Godwin,et al.  Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.

[101]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[102]  Satoshi O. Suzuki,et al.  MAP‐2e, a Novel MAP‐2 Isoform, Is Expressed in Gliomas and Delineates Tumor Architecture and Patterns of Infiltration , 2002, Journal of neuropathology and experimental neurology.

[103]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  W. Cavenee,et al.  Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. , 2001, Journal of neurosurgery.

[105]  A. Scott,et al.  Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.

[106]  A. Scott,et al.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.

[107]  H. Poulsen,et al.  The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  D. Bigner,et al.  EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.

[109]  Xue-Qing Wang,et al.  Post-transcriptional Regulation of the GLI1 Oncogene by the Expression of Alternative 5′ Untranslated Regions* , 2001, The Journal of Biological Chemistry.

[110]  C. James,et al.  Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. , 2001, Genomics.

[111]  J. Laterra,et al.  Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. , 2000, Biochemical and biophysical research communications.

[112]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[113]  G. Fuller,et al.  Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. , 2000, Cancer research.

[114]  S. Howng,et al.  Differential expression of four human dynamin-like protein variants in brain tumors. , 2000, DNA and cell biology.

[115]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[116]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[117]  M. Berger,et al.  Suppression of glioblastoma cell growth following antisense oligonucleotide‐mediated inhibition of fibroblast growth factor receptor expression , 1999, Glia.

[118]  W. Jin,et al.  Redundant Intronic Repressors Function to Inhibit Fibroblast Growth Factor Receptor-1 α-Exon Recognition in Glioblastoma Cells* , 1999, The Journal of Biological Chemistry.

[119]  M. Seiki,et al.  Regulation of matrix metalloproteinase‐2 (MMP‐2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP‐2 expression and activation accompanying up‐regulation of membrane type‐1 MMP , 1999, International journal of cancer.

[120]  G. Viale,et al.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. , 1999, The American journal of pathology.

[121]  B. Badie,et al.  In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. , 1999, Neurosurgery.

[122]  F. Neff,et al.  Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild‐type p53 protein in human glioblastoma cells , 1999, International journal of cancer.

[123]  A. Strasser,et al.  The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. , 1999, Molecular cell.

[124]  Y. Lazebnik,et al.  Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. , 1999, Cancer research.

[125]  S. Feller,et al.  Physiological signals and oncogenesis mediated through Crk family adapter proteins , 1998, Journal of cellular physiology.

[126]  H. Kataoka,et al.  Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. , 1998, Biochemical and biophysical research communications.

[127]  W. Jin,et al.  Exon Sequence Is Required for Regulated RNA Splicing of the Human Fibroblast Growth Factor Receptor-1 α-Exon* , 1998, The Journal of Biological Chemistry.

[128]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[129]  H. Abe,et al.  Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. , 1998, Cancer research.

[130]  B. Stoddard,et al.  The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. , 1998, Structure.

[131]  Marlys Witte,et al.  Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells , 1998, International journal of cancer.

[132]  H. Poulsen,et al.  Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  W. Cavenee,et al.  Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[134]  E. Rosen,et al.  Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[135]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[136]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[137]  N. Maihle,et al.  A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. , 1996, Nucleic acids research.

[138]  W. Cavenee,et al.  EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.

[139]  M. Kan,et al.  Ligand-specific Structural Domains in the Fibroblast Growth Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[140]  M. Kan,et al.  Alternately Spliced NH2-terminal Immunoglobulin-like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for both Heparin and FGF-1(*) , 1995, Journal of Biological Chemistry.

[141]  M. Dours-Zimmermann,et al.  A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. , 1994, The Journal of biological chemistry.

[142]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[143]  G. Hannon,et al.  KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[144]  J. Bruner,et al.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[145]  L. Zardi,et al.  Cell-cycle dependent alternative splicing of the tenascin primary transcript. , 1994, Cell adhesion and communication.

[146]  S. Werner,et al.  Targeted expression of a dominant‐negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. , 1993, The EMBO journal.

[147]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[148]  T. Habib,et al.  Epidermal growth factor (EGF)-stimulated tyrosine phosphorylation and EGF receptor degradation in cells expressing EGF receptors truncated at residue 973. , 1992, The Journal of biological chemistry.

[149]  J. Rubin,et al.  Identification of a competitive HGF antagonist encoded by an alternative transcript. , 1991, Science.

[150]  P. Humphrey,et al.  Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. , 1991, Biochemical and biophysical research communications.

[151]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[152]  G. M. Walton,et al.  Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation , 1989, Cell.

[153]  R. Coleman,et al.  Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. , 1989, Cancer research.

[154]  P. Humphrey,et al.  Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.

[155]  J. Trent,et al.  Identification of an amplified, highly expressed gene in a human glioma. , 1987, Science.

[156]  D. Burk,et al.  On respiratory impairment in cancer cells. , 1956, Science.

[157]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[158]  S. Weinhouse On respiratory impairment in cancer cells. , 1956, Science.